Zachariae C, et al. - Experts evaluated the 4-year efficacy and safety of ixekizumab in moderate-to-severe psoriasis patients in the open-label extension (OLE) of this phase 2 trial. As per data, patients received ixekizumab 120 mg then 80 mg subcutaneously once every 4 weeks. They noted that for up to 4 years of ixekizumab treatment, efficacy was maintained. When compared to baseline, Dermatology Life Quality Index and Itch Visual Analog Scale scores decreased. Results demonstrated improvements in other efficacy and health outcome measures.